More than a snapshot in time: Supplementary vital sign offers deeper insight into long-term health risks

Premstaetten, Austria, and Munich, Germany (May 27, 2026) — Heart rate, blood flow, and other physiological metrics have been central to health monitoring for decades. However, numerous relevant changes in the human body develop insidiously over time and may go undetected when relying on single measurements. As a result, there is increasing interest in supplementary vital signs that reflect sustained physiological strain. One such approach is the non-invasive assessment of Advanced Glycation End Product (AGE) accumulation in tissue via skin autofluorescence.


“Established vital signs continue to be a cornerstone of health monitoring,” says Stephan Haslbeck, Product Manager at ams OSRAM. “Fascinating potential emerges when additional metrics enable projections that extend further into the future: They supplement momentary snapshots with indicators of long-term physiological burdens and thus make it easier to interpret health trends over time.”


A vital sign that reflects long-term trends
AGEs are formed through natural metabolic processes and accumulate in body tissue over extended periods of time. In contrast to heart rate and blood flow, their levels do not fluctuate rapidly in response to physical activity, stress, or an individual’s daily condition. Instead, they change gradually, reflecting ongoing physiological strain over time.

The AGE value does not indicate how an individual is doing right now, but rather reflects the metabolic and physiological processes of strain that has shaped a body[IP2.1] over time. It acts as a biological long-term memory, with continuous measurements revealing the physiological burdens that have accumulated inside the body over the years. In medical research, elevated AGE levels have been associated with metabolic and vascular stress, as seen in conditions such as diabetes, reduced kidney function, and cardiovascular disorders. 

What enables this non-invasive approach is a particular characteristic of certain AGEs in tissue: They accumulate over extended periods in collagen-rich skin tissue and emit a measurable fluorescent signal under targeted optical excitation. This effect can be detected from outside the body, offering a way to visualize long-term biological processes through the skin without the need for blood sampling or invasive procedures.


How to integrate new measurement approaches into compact systems
To make use of additional vital signs like AGE in practice, it must be possible to integrate them into compact, safe, and robust systems. To achieve this, state-of-the-art optical sensing technology enables a clear distinction between different optical signals within a single system.

One representative example is the SFH 7019 multi-chip LED from ams OSRAM. It combines three wavelengths relevant to vital sign applications in a compact component measuring 1.65 mm × 2.15 mm × 0.6 mm (0,065 x 0,084 x 0,0232 in): UV-A light (typically ~383 nm) to excite tissue autofluorescence; green light (~530 nm) for established vital signs such as heart rate monitoring as well as for reflection correction; and infrared light (~980 nm) for photoplethysmography[IP3.1] (PPG)-based measurements. The individual chips can be controlled separately, allowing different measurement approaches to be applied at different times.

Complementing the light source is a specially designed photodiode configured for the concurrent detection of both autofluorescence and PPG signals. An integrated filter reliably blocks UV excitation while allowing the detection of visible and infrared light. Various optical measurements can thus be conducted in a single system without significant mutual interference, ensuring high measurement accuracy.


Prevention and health trajectories in focus
The key benefit of such systems lies in the enrichment of established vital signs with additional insights. Short-term measurements still provide the necessary overview of the current state, while long-term indicators allow for a more informed interpretation of changes over time.

This opens up new possibilities for wearables, home care, and other near-patient applications — particularly in prevention-oriented settings that demand a broader view of long-term health trends. 

You can find information on the product portfolio for vital sign monitoring here. 
 

The SFH 7019 multi-chip LED from ams OSRAM combines chips emitting green (530 nm), infrared (980 nm), and UV-A (382 nm) light.
Photo: ams OSRAM

A matching SFH 2705U photodiode blocks UV light from reaching the detector, thereby enhancing the accuracy of skin autofluorescence measurements.
Photo: ams OSRAM

The new wavelength combination enables both heart rate monitoring and AGE measurement.
Photo: ams OSRAM

ams OSRAMについて

ams OSRAM Group(SIX:AMS)は、革新的な光とセンサソリューションのグローバルリーダーです。デジタルフォトニクスのスペシャリストとして、優れたエンジニアリング能力と最先端のグローバルな製造能力を兼ね備え、お客様にデジタル照明やセンシングテクノロジーの多彩なポートフォリオを提供しています。

「光の力を感じよう」–当社の成功は、光が持つ可能性に対する深い理解を基盤としてきました。120年にわたり、自動車、工業生産、医療、コンシューマー向け電子機器などの市場に変革をもたらすイノベーションを創出してきました。OSRAMブランドの記念となる本年には、世界で約18,500人の従業員が、スマートモビリティ、人工知能、拡張現実、スマートヘルス、ロボティクスといった社会のメガトレンドに沿った先駆的なソリューションの開発に注力しています。これは、12,000件を超える特許の取得・出願に反映されています。オーストリアのプレムシュテッテン/グラーツに本社を置き、ドイツ・ミュンヘンに共同の本社を設置しています。当グループは2025年に33億ユーロの収益を達成しており、ams-OSRAM AGは、スイス証券取引所に上場しています(ISIN:AT0000A3EPA4)。

詳細情報はこちらをご覧ください:https://ams-osram.cn

amsとOSRAMは、ams-OSRAM AGの登録商標です。また、当社製品およびサービスの多くはams OSRAM Groupの商標または登録商標です。ここで記載されるその他全ての企業名および製品名は、各所有者の商標または登録商標である場合があります。   
 
ams OSRAMのソーシャルメディアチャンネルをご購読ください:>LinkedIn  >YouTube 

\n